A changing world for DCvax: A PSMA loaded autologous dendritic cell vaccine for prostate cancer

Expert Opinion on Biological Therapy

Volumn 9, Issue 12, 2009, Pages 1565-1575

  Fishman, Mayer ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Dendritic cell vaccine; Immunotherapy; Prostate cancer; PSMA

Indexed keywords

ABARELIX; ABIRATERONE ACETATE; AMG 102; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BICALUTAMIDE; CALCITRIOL; DEGARELIX; DENDRITIC CELL VACCINE; DOCETAXEL; ESTROGEN; FLUTAMIDE; GOSERELIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMC 1121B; IMC A12; IXABEPILONE; KETOCONAZOLE; LEUPRORELIN; MDV 3100; MITOXANTRONE; MKC 1006PP; MKC 1106PP; NILUTAMIDE; PHYTOESTROGEN; PREDNISONE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROVENGE; RENIALE; SATRAPLATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITESPEN;

ADD ON THERAPY; ANTIGEN PRESENTATION; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CASTRATION; CHILL; CLINICAL TRIAL; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HUMAN; HYPERTENSION; IMMUNOGENICITY; PEER REVIEW; PROSTATE CANCER; REVIEW; SIDE EFFECT; SWEATING; T LYMPHOCYTE; TREATMENT RESPONSE; VIROTHERAPY;

ANIMALS; ANTIGENS, SURFACE; CANCER VACCINES; DENDRITIC CELLS; DRUG APPROVAL; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; PROSTATIC NEOPLASMS; TISSUE EXTRACTS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 70450162100     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590903446921     Document Type: Review

References (78)

1. Papers of special note have been highlighted as either of interest (.) or of considerable interest (..) to readers.
2. Surveillance, epidemiology and end results. Bethesda, MD: National Cancer Institute, 2009. Available from: http://seer.cancer.gov/ [Last accessed 30 October 2009]
3. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003;95(17):1276-1299
4. Wilt TJ, MacDonald R, Rutks I, et al. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008;148(6):435-448
5. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2009;181(5):1998-2006, discussion 2007-2008
6. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360(13):1320-1328
7. Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008;100(23):1672-1694
8. Baradaran N, Ahmadi H, Salem S, et al. The protective effect of diabetes mellitus against prostate cancer: Role of sex hormones. Prostate 2009;69(16):1744-1750
9. Gong Z, Kristal AR, Schenk JM, et al. Alcohol consumption, finasteride, and prostate cancer risk: Results from the prostate cancer prevention trial. Cancer 2009;115(16):3661-3669
10. Kaplan SA, Roehrborn CG, Meehan AG, et al. PCPT: evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer. Urology 2009;73(5):935-939
11. Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99(18):1375-1383
12. Musquera M, Fleshner NE, Finelli A, Zlotta AR. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride. Expert Rev Anticancer Ther 2008;8(7):1073-1079
13. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009;301(1):39-51
14. Damber JE, Aus G. Prostate cancer. Lancet 2008;371(9625):1710-1721
15. Galsky MD, Simon K, Sonpavde G, et al. Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer. Ann Oncol 2009;20(5):965-966
16. Yap TA, Carden CP, Attard G, de Bono JS. Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol 2008;8(4):449-457
17. Small EJ, Baron AD, Fippin L, Apodaca D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 1997;157(4):1204-1207
18. Small EJ, Frohlich MW, Bok R, et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 2000;18(21):3595-3603 . Product characterization after the trial completion showed significant lot-to-lot variability, which is a factor in limited further formal development of non-prescription phyto-estrogen supplements.
19. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-1520
20. Sartor AO, Petrylak DP, Witjes JA, et al. Satraplatin in patients with advanced hormone-refractory prostate cancer (HRPC): overall survival (OS) results from the phase III satraplatin and prednisone against refractory cancer (SPARC) trial. J Clin Oncol 2008;26(suppl):, abstract 5003
21. Krishnan AV, Moreno J, Nonn L, et al. Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: Role of anti-inflammatory activity. J Bone Miner Res 2007;22(Suppl 2):V74-80
22. Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007;25(6):669-674
23. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14(6):1756-1764
24. Scher HI, Beer TM, Higano CS, et al. Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC) [abstract 5011]. J Clin Oncol 2009;27(Suppl):15s
25. Reid AH, Attard G, Danila D, et al. A multicenter phase II study of abiraterone acetate (AA) in docetaxel pretreated castration-resistant prostate cancer (CRPC) patients (pts) [abstract 5047]. J Clin Oncol 2009;27(Suppl):15s . The concept of 'retained hormone sensitivity' after chemotherapy treatment is strengthened by this post-docetaxel application.
26. Ryan C, Efstathiou E., Smith M, et al. Phase II multicenter study of chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone [abstr 5046]. J Clin Oncol 2009;27(Suppl):15s .. The abstract presentation of a singlearm experience on which the pivotal trial is based.
27. Nelson JB, Love W, Chin JL, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008;113(9):2478-2487
28. Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007;110(9):1959-1966
29. Sonpavde G, Periman PO, Bernold D, et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2009; published online 24 July 2009, doi:10.1093/annonc/mdp323 . One of multiple trial efforts applying anti-VEGF strategies in prostate cancer.
30. Ruter J, Barnett BG, Kryczek I, et al. Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Front Biosci 2009;14:1761-1770
31. Nicholaou T, Ebert LM, Davis ID, et al. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res 2009;15(6):2166-2173
32. Mazzaferro V, Coppa J, Carrabba MG, et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 2003;9(9):3235-3245
33. Zea AH, Rodriguez PC, Culotta KS, et al. L-Arginine modulates CD3z expression and T cell function in activated human T lymphocytes. Cell Immunol 2004;232(1-2):21-31 . This paper describes how methods to quantify the effector/lymphocyte compartment function are being understood in parallel with the dendritic cell phenotype issues.
34. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004;4(12):941-952 .. This paper describes how advances in dendritic cell biology and myeloid suppressor biology and pathophysiology may markedly improve the quantitation of cancer-induced immune tolerant phenotype.
35. Baccala A, Sercia L, Li J, et al. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology 2007;70(2):385-390
36. Chang SS, Reuter VE, Heston WD, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59(13):3192-3198
37. Mhawech-Fauceglia P, Zhang S, Terracciano L, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology 2007;50(4):472-483
38. Elsasser-Beile U, Bühler P, Wolf P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets 2009;10(2):118-125
39. Olson WC, Heston WD, Rajasekaran AK. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials 2007;2(3):182-190
40. Slovin SF. Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen. Expert Opin Ther Targets 2005;9(3):561-570
41. Low L, Mander A, McCann KJ, et al. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 2009; published online 24 September 2009, doi:10.1089/hum.2009.067
42. Liu C, Hasegawa K, Russell SJ, et al. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. Prostate 2009;69(10):1128-1141
43. Galsky MD, Eisenberger M, Moore-Cooper S, et al. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol 2008;26(13):2147-2154
44. Morris MJ, Divgi CR, Pandit-Taskar N, et al. Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin Cancer Res 2005;11(20):7454-7461
45. Bander NH, Milowsky MI, Nanus DM, et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005;23(21):4591-4601
46. Waeckerle-Men Y, Uetz-von Allmen E, Fopp M, et al. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother 2006;55(12):1524-1533
47. Fuessel S, Meye A, Schmitz M, et al. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: Results of a phase I clinical trial. Prostate 2006;66(8):811-821
48. Lodge PA, Jones LA, Bader RA, et al. Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res 2000;60:829-833
49. Sawant RM, Cohen MB, Torchilin VP, Rokhlin OW. Prostate cancer-specific monoclonal antibody 5D4 significantly enhances the cytotoxicity of doxorubicin-loaded liposomes against target cells in vitro. Drug Target 2008;16(7):601-604
50. Bühler P, Molnar E, Dopfer EP, et al. Target-dependent T-cell activation by coligation with a PSMA- CD3 diabody induces lysis of prostate cancer cells. J Immunother 2009;32(6):565-573
51. Kuratsukuri K, Wang CY, Sone T, et al. Induction of antibodies against prostate-specific membrane antigen (PSMA) by vaccination with a PSMA DNA vector. Eur Urol 2002;42(1):67-73
52. Medin JA, Liang SB, Hou JW, et al. Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo. Cancer Gene Ther 2005;12(6):540-551
53. Wang K, Gao X, Pang J, et al. Dendritic cells transduced with a PSMA-encoding adenovirus and cocultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against prostate cancer cells. Urol Oncol 2009;27(1):26-32
54. O'Keefe DS, Uchida A, Bacich DJ, et al. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate 2000;45(2):149-157
55. Durso RJ, Andjelic S, Gardner JP, et al. A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses. Clin Cancer Res 2007;13(13):3999-4008
56. Tjoa BA, Lodge PA, Salgaller ML, et al. Dendritic cell-based immunotherapy for prostate cancer. CA Cancer J Clin 1999;49(2):117-128, 65 .. This paper aggregates the data on the patients who have been treated in several trials [56-59]
57. Tjoa BA, Erickson SJ, Bowes VA, et al. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 1997;32(4):272-278
58. Murphy GP, Tjoa BA, Simmons SJ, et al. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 1999;38(1):73-78
59. Tjoa BA, Simmons SJ, Bowes VA, et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998;36(1):39-44
60. Zeng G. MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design. J Immunother 2001;24(3):195-204
61. Peshwa MV, Shi JD, Ruegg C, et al. Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate 1998;36(2): 129-138
62. Rini BI, Weinberg V, Fong L, et al. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 2006;107(1):67-74
63. Beinart G, Rini BI, Weinberg V, Small EJ. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer 2005;4(1):55-60
64. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009;115(16):3670-3679
65. Schellhammer PF, Higano C, Berer ER, et al. A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipleucel-T in men with metastatic, androgen-independent prostate adenocarcinoma (AIPC). Presented by P Kantoff, AUA meeting 4/28/2009, late breaking abstracts
66. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24(19):3089-3094
67. Higano CS, Corman JM, Smith DC, et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008;113(5):975-984
68. Burch PA, Croghan GA, Gastineau DA, et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a phase 2 trial. Prostate 2004;60(3):197-204
69. Small EJ, Sacks N, Nemunaitis J, et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 2007;13(13):3883-3891
70. Available from: clinical trials.gov, search "GVAX"
71. GVAX immunotherapy for prostate cancer. San Francisco California: Cell Genesys, 2009. Available from: http:// www.cellgenesys.com/view.cfm/20/GVAX- Immunotherapy-for-Prostate- Cancer [Last accessed 30 October 2009]
72. Update of long-term data on brain cancer patients receiving DCVax--Brain continues to show striking improvements in delay of disease and survival. Bethesda MD: Northwest Biotherapeutics, press release date 17 February 2009. Avaliable from: http://www.nwbio.com/pdf/ press2009.02.17-us.pdf [Last accessed 30 October 2009]
73. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-996
74. Information available from: www.nwbio.com
75. Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004;363(9409):594-599
76. Wood C, Srivastava P, Bukowski R, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008;372(9633):145- 154
77. Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008;105(8):3005-3010
78. Harzstark AL, Small EJ. Immunotherapeutics in development for prostate cancer. Oncologist 2009;14(4):391-398